System and method for detection of a biological condition

• US 6,363,772 B1
• Filed: 12/10/1999
• Issued: 04/02/2002
• Est. Priority Date: 12/10/1999
• Status: Expired due to Fees

• Current Assignee: Edward Q. Yavitz
• Original Assignee: Quadrivium, LLC
• Inventors: Berry, Michael J.
• Primary Examiner(s): Warden, Jill
• Assistant Examiner(s): Sines, Brian J.
• Application Number:
  US09/459,251
• Time in Patent Office: 844 Days
• Field of Search: 436/164, 250/227.24, 250/343, 250/339.13, 73/240.2, 73/614.9, 73/240.1, 73/240.6, 73/300.4, 73/310.5, 356/432, 356/437
• US Class Current: 73/24.02
• CPC Class Codes: G01N 2021/1704 in gases
• CPC Class Codes: G01N 21/1702 with opto-acoustic detection, e.g. for gases or analysing solids
• CPC Class Codes: G01N 23/02 by transmitting the radiation through the material

Abstract

A system and method that allows for early detection of biological conditions, such as a disease, through analysis of appropriate gaseous samples. The system and method are particularly amenable to the early screening for diseases, such as lung cancer, through the detection of specific biomarkers when present in exhaled breath from an individual. A preferred system implements a CO overtone laser that generates radiation and directs it through a photoacoustic cell. The absorption of the radiation is detected acoustically, and the absorption characteristics are utilized in determining the presence of a specific biological condition.

Claims

1. A system for detecting a biomarker indicative of the presence of a biological condition, comprising:

a photoacoustic cell having an inlet through which a gaseous sample may be introduced into an interior of the photoacoustic cell;

an overtone laser combined with the photoacoustic cell, the overtone laser being positioned to direct a radiation through the photoacoustic cell, the radiation being of a frequency predetermined for a characteristic intense absorption by at least one specific biomarker contained in the gaseous sample, wherein the overtone laser comprises a CO overtone laser; and

a detection system coupled to the photoacoustic cell to detect the characteristic intense absorption indicative of the at least one specific biomarker.

2. The system as recited in claim 1, wherein the overtone laser includes an optical cavity and the photoacoustic cell is disposed within the optical cavity.

4. The system as recited in claim 1, wherein the detection system comprises a microphone.

5. The system as recited in claim 1, further comprising an acoustic signal enhancer.

6. The system as recited in claim 1, wherein the biomarker comprises a volatile organic compound present in the gaseous sample.

7. The system as recited in claim 6, wherein the volatile organic compound is an indicator of lung cancer.

3. A system for detecting a biomarker indicative of the presence of a biological condition, comprising:

a photoacoustic cell having an inlet through which a gaseous sample may be introduced into an interior of the photoacoustic cell;

an overtone laser combined with the photoacoustic cell, the overtone laser being positioned to direct a radiation through the photoacoustic cell, the radiation being of a frequency predetermined for a characteristic intense absorption by at least one specific biomarker contained in the gaseous sample, wherein the overtone laser uses CO overtone laser transitions based on Δ

v=−

2 overtone band sequence; and

a detection system coupled to the photoacoustic cell to detect the characteristic intense absorption indicative of the at least one specific biomarker.

8. The system as recited in claim 3, wherein the biomarker comprises a volatile organic compound present in the gaseous sample.

10. The system as recited in claim 3, wherein the overtone laser includes an optical activity and the photoacoustic cell is disposed within the optical cavity.

11. The system as recited in claim 3, wherein the detection system comprises a microphone.

12. The system as recited in claim 3, further comprising an acoustic signal enchancer.

9. The system as recited in claim wherein 8, the volatile organic compound is an indicator of lung cancer.